基础医学与临床 ›› 2012, Vol. 32 ›› Issue (3): 354-357.

• 短篇综述 • 上一篇    下一篇

甲氨蝶呤治疗类风湿关节炎的新思考

马亚1,曾学军2   

  1. 1. 中国医学科学院,北京协和医学院,北京协和医院
    2. 中国医学科学院 北京协和医学院 北京协和医院
  • 收稿日期:2011-11-16 修回日期:2011-12-26 出版日期:2012-03-05 发布日期:2012-02-27
  • 通讯作者: 曾学军 E-mail:zxjpumch@126.com

Methotrexate is a new consideration in treatment of rheumatoid

Ya MA1,Xue-jun ZENG2   

  1. 1. PUMC hospital,CAMS & PUMC
    2.
  • Received:2011-11-16 Revised:2011-12-26 Online:2012-03-05 Published:2012-02-27
  • Contact: Xue-jun ZENG E-mail:zxjpumch@126.com

摘要: 摘要:甲氨蝶呤(MTX)为目前治疗类风湿关节炎(RA)首选的改善病情抗风湿药(DMARDs)。MTX在减轻症状和体征、减少致残及延缓影像学结构破坏等方面优于其他DMARDs。在生物制剂和MTX等传统DMARDs之间进行选择时,需充分考虑成本效益因素以保障患者的依从性和病情缓解。预测MTX治疗反应性或安全性的生物或基因标记物可指导临床医生制定最佳的RA治疗方案。

关键词: 类风湿关节炎, 甲氨蝶呤, 治疗, 生物制剂

Abstract: Absract: MTX is the most commonly used DMARDs of first choice. In comparison with other DMARDs, MTX is more effective in reducing signs and symptoms, disability and radiographic structural damage. In order to ensure the compliance and remission of patients, cost-effectiveness should be taken into consideration when choose between the biological agents and traditional DMARDs such as MTX. Searching proper biological or genetic markers predicting the safety and efficacy to MTX may optimize the treatment of RA.

Key words: rheumatoid arthritis, methotrexate, therapy, biologics

中图分类号: